Concepedia

Author

Rainer Fietkau

Friedrich-Alexander-Universität Erlangen-Nürnberg

Also Known As

Fietkau, Rainer, K. Kraft, P. Feyer, R Fietkau, R. Fietkau, Rainer Fietkau, Rainer J. Fietkau

264

Publications

17K

Citations

44

H-Index

72

Concepts

All Affiliations

Friedrich-Alexander-Universität Erlangen-NürnbergUniversitätsklinikum ErlangenGoethe University FrankfurtUniversity of RostockUniversity Hospital Frankfurt
RF

About

Rainer Fietkau is an author at Friedrich-Alexander-Universität Erlangen-Nürnberg specializing in radiation oncology, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

36

3.3K

2

Health Sciences

13

13

838

3

Cell Biology

2

2

49

4

Engineering

1

1

36

5

Gastroenterology

1

1

108

Rainer Fietkau

×

82

Publications

15.2K

Citations

39

H-Index

YearCitations

Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer

Rolf Sauer, Heinz Becker, Werner Hohenberger,

New England Journal of Medicine

2004

6K

Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years

Rolf Sauer, Torsten Liersch, Susanne Merkel,

Journal of Clinical Oncology

2012

2.1K

Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer

Claus Rödel, Peter Martus, Thomas Papadoupolos,

Journal of Clinical Oncology

2005

1.2K

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

Claus Rödel, Ullrich Graeven, Rainer Fietkau,

The Lancet Oncology

2015

713

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial

Claus Rödel, Torsten Liersch, Heinz Becker,

The Lancet Oncology

2012

694

Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial

Emmanouil Fokas, Torsten Liersch, Rainer Fietkau,

Journal of Clinical Oncology

2014

453

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer

Henriette Golcher, Thomas Brunner, Helmut Witzigmann,

Strahlentherapie und Onkologie

2014

327

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido,

Journal of Thoracic Oncology

2022

203

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra,

The Lancet Oncology

2024

174

Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)

Michaël Baumann, Thomas Herrmann, R. Koch,

Radiotherapy and Oncology

2011

152

Page 1